Cargando…
Exploratory analysis of interleukin‐38 in hospitalized COVID‐19 patients
INTRODUCTION: A major contributor to coronavirus disease 2019 (COVID‐19) progression and severity is a dysregulated innate and adaptive immune response. Interleukin‐38 (IL−38) is an IL‐1 family member with broad anti‐inflammatory properties, but thus far little is known about its role in viral infec...
Autores principales: | de Graaf, Dennis M., Teufel, Lisa U., de Nooijer, Aline H., van Gammeren, Adriaan J., Ermens, Antonius A. M., Gaál, Ildikó O., Crișan, Tania O., van de Veerdonk, Frank L., Netea, Mihai G., Dinarello, Charles A., Joosten, Leo A. B., Arts, Rob J. W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601778/ https://www.ncbi.nlm.nih.gov/pubmed/36301025 http://dx.doi.org/10.1002/iid3.712 |
Ejemplares similares
-
IL‐38 prevents induction of trained immunity by inhibition of mTOR signaling
por: de Graaf, Dennis M., et al.
Publicado: (2021) -
Opposing Effects of Interleukin-36γ and Interleukin-38 on Trained Immunity
por: Teufel, Lisa U., et al.
Publicado: (2023) -
Circulating interleukin-38 concentrations in healthy adults
por: Teufel, Lisa U., et al.
Publicado: (2022) -
Reduced concentrations of the B cell cytokine interleukin 38 are associated with cardiovascular disease risk in overweight subjects
por: de Graaf, Dennis M., et al.
Publicado: (2020) -
Protective host defense against disseminated candidiasis is impaired in mice expressing human interleukin-37
por: van de Veerdonk, Frank L., et al.
Publicado: (2015)